- This historic approval provides a new treatment option that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy and generates elevated and sustained factor IX ...
Dear ANCA‑associated vasculitis community, We are writing to share an important update on TAVNEOS® (avacopan) in the European Union (EU). The European Medicines Agency’s (EMA’s) Committee for ...
We are writing to share an important update on the availability of HEMGENIX ® (etranacogene dezaparvovec-drlb). CSL is currently experiencing a temporary global stockout of HEMGENIX ® that will result ...
Read more about An Update on TAVNEOS® (avacopan) in the European Union: Our commitment to continued support for the ANCA Associated Vasculitis Community Large cluster-randomized crossover study ...
ST. GALLEN, SWITZERLAND – 26 June 2026 Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human ...
ST. GALLEN, Switzerland and SAN DIEGO, April 29, 2025 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) are pleased to announce that the European Commission has approved the ...
New $1.5 billion investment builds on over $3 billion already spent on CSL's U.S. operations since 2018 Expansion will create at least 300 new jobs and enhance production of plasma-derived therapies ...
Summit, New Jersey, USA | 21 October, 2025 – CSL Seqirus, a global leader in seasonal influenza prevention (ASX: CSL), has shared new actionable real-world evidence (RWE) reinforcing the critical role ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results